nach oben

International Urology and Nephrology

Erschienen in:

01.08.2012 | Nephrology – Translational Section

IgA nephropathy and oxidative stress: news on clinically evaluated biomarkers hits the stage

verfasst von: Cheng Zhu, Peter R. Mertens

Erschienen in: International Urology and Nephrology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Excerpt

Galactose-deficient IgA1 (Gd-IgA1) plays a central role in the pathogenesis of IgA nephropathy (IgAN) [1‐3]. However, high levels of circulating Gd-IgA1 are not sufficiently predictive regarding IgAN progression [4, 5]. In a recent publication in the Clinical Journal of the American Society of Nephrology by Camilla et al. (Regina Margherita University hospital, Italy), the circulating oxidative stress level, assessed by advanced oxidation protein products, outperformed Gd-IgA1 level determinations and predicted best the progressive kidney disease in a cohort of 292 patients diagnosed with IgA nephropathy [6]. …

Suzuki H et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22(10):1795–1803PubMedCrossRef

Mestecky J et al (2007) IgA nephropathy: current views of immune complex formation. Contrib Nephrol 157:56–63PubMed

Moldoveanu Z et al (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71(11):1148–1154PubMedCrossRef

Coppo R, Feehally J, Glassock RJ (2010) IgA nephropathy at two score and one. Kidney Int 77(3):181–186PubMedCrossRef

Gharavi AG et al (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19(5):1008–1014PubMedCrossRef

Camilla R et al (2011) Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6(8):1903–1911PubMedCrossRef

Berger J, Hinglais N (1968) Intercapillary deposits of IgA–IgG. J Urol Nephrol (Paris) 74(9):694–695

D’Amico G (1987) The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64(245):709–727PubMed

Suzuki K et al (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63(6):2286–2294PubMedCrossRef

10.

Waldherr R et al (1989) Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transpl 4(11):943–946

11.

Barratt J et al (2009) Immune complex formation in IgA nephropathy: a case of the ‘right’ antibodies in the ‘wrong’ place at the ‘wrong’ time? Nephrol Dial Transpl 24(12):3620–3623CrossRef

12.

Floege J (2011) The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 58(6):992–1004PubMedCrossRef

13.

Conley ME, Cooper MD, Michael AF (1980) Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66(6):1432–1436PubMedCrossRef

14.

Tomino Y et al (1981) Immunoglobulin A1 and IgA nephropathy. N Engl J Med 305(19):1159–1160PubMedCrossRef

15.

Russell MW et al (1986) IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 6(1):74–86PubMedCrossRef

16.

Allen AC et al (2001) Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60(3):969–973PubMedCrossRef

17.

Hiki Y et al (2001) Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59(3):1077–1085PubMedCrossRef

18.

Coppo R, Amore A (2004) Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 65(5):1544–1547PubMedCrossRef

19.

Novak J et al (2008) IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 28(1):78–87PubMedCrossRef

20.

Tomana M et al (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104(1):73–81PubMedCrossRef

21.

Mestecky J et al (2008) Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 31(1):29–37PubMedCrossRef

22.

Novak J et al (2002) Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 62(2):465–475PubMedCrossRef

23.

Novak J et al (2005) IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 67(2):504–513PubMedCrossRef

24.

Shimozato S et al (2008) Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Nephrol Dial Transpl 23(6):1931–1939CrossRef

25.

Descamps-Latscha B et al (2004) Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int 66(4):1606–1612PubMedCrossRef

26.

Durackova Z (2010) Some current insights into oxidative stress. Physiol Res 59(4):459–469PubMed

27.

Witko-Sarsat V et al (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49(5):1304–1313PubMedCrossRef

28.

Witko-Sarsat V et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161(5):2524–2532PubMed

29.

Roberts IS et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76(5):546–556PubMedCrossRef

30.

Moriyama, T., et al. (2012) Severity of nephrotic IgA nephropathy according to the Oxford classification. Int Urol Nephrol

31.

Shi XY et al (2008) Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149(4):1829–1839PubMedCrossRef

32.

Liu SX et al (2006) Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26(5):1156–1162PubMedCrossRef

33.

Zuwala-Jagiello J et al (2011) Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis. Acta Biochim Pol 58(1):59–65PubMed

34.

Wei XF et al (2009) Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. Am J Physiol Renal Physiol 296(2):F427–F437PubMedCrossRef

35.

Zhou LL et al (2009) Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int 76(11):1148–1160PubMedCrossRef

36.

Wen YK (2010) Comparison of prominent glomerular injury and prominent tubular injury in immunoglobulin a nephropathy. Int Urol Nephrol 42(3):753–758PubMedCrossRef

37.

Torres DD et al (2008) The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73(3):327–333PubMedCrossRef

Titel: IgA nephropathy and oxidative stress: news on clinically evaluated biomarkers hits the stage
verfasst von: Cheng Zhu
Peter R. Mertens
Publikationsdatum: 01.08.2012
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 4/2012
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-012-0201-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

IgA nephropathy and oxidative stress: news on clinically evaluated biomarkers hits the stage

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Quality of life and protein-energy wasting in kidney transplant recipients

The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml

Metastatic pulmonary calcification in chronic renal failure

Rhabdomyolysis with acute kidney injury in deceased donors is not a contraindication for kidney donation

CRP and acute renal rejection: a marker to the point

Is sampling transitional zone in patients who had prior negative prostate biopsy necessary?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Innere Medizin